Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Johnson & Johnson $JNJ Shares Purchased by America First Investment Advisors LLC
03:08am, Wednesday, 19'th Nov 2025
America First Investment Advisors LLC boosted its stake in shares of Johnson and Johnson (NYSE: JNJ) by 0.2% during the undefined quarter, according to its most recent Form 13F filing with the Securit
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
12:06pm, Tuesday, 18'th Nov 2025
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
3 Smart Defensive Stocks for an Uneasy Market
10:07am, Tuesday, 18'th Nov 2025
At one point in early November, the Dow Jones Industrial Average (DJIA) briefly topped 48,000 for the first time ever. At different times in 2025, the NASDAQ and S&P 500 have made new all-time highs (
Johnson & Johnson Expands Oncology Pipeline with $3.05 Billion Halda Acquisition
01:16am, Tuesday, 18'th Nov 2025
Johnson and Johnson (JNJ, Financials) agreed to buy privately held Halda Therapeutics for $3.05 billion in cash, expanding its cancer portfolio with a focus on so
LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio acquisition of 2025, capping an unprece
Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
01:17pm, Monday, 17'th Nov 2025
Johnson & Johnson ( JNJ ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 10:40 AM EST Company Participants Candice Long - Worldwide Vice President of Immunology David Lee - Global T
Johnson & Johnson strengthens oncology portfolio with $3B Halda Therapeutics acquisition
11:51am, Monday, 17'th Nov 2025
Johnson & Johnson (NYSE:JNJ) announced that it has entered into a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotechnology company focused on developing targeted oral therapi
Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment
09:39am, Monday, 17'th Nov 2025
Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.
Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion
08:29am, Monday, 17'th Nov 2025
Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant's oncology pipeline.
Halda Therapeutics Announces Acquisition by Johnson & Johnson
08:15am, Monday, 17'th Nov 2025
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics announced today that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire Halda for $3.05
Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ
08:11am, Monday, 17'th Nov 2025
Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.
J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion
08:07am, Monday, 17'th Nov 2025
Johnson & Johnson said on Monday it would buy Halda Therapeutics for $3.05 billion in cash, expanding its presence in solid tumors and prostate cancer treatments.
First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety pro
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics
08:00am, Monday, 17'th Nov 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage b
Alberta Investment Management Corp Sells 109,135 Shares of Johnson & Johnson $JNJ
03:30am, Monday, 17'th Nov 2025
Alberta Investment Management Corp cut its position in Johnson and Johnson (NYSE: JNJ) by 85.4% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 18,700 sh
